UBI – Siemens announces full launch of Award Winning Xprecia Stride™ Coagulation Analyzer

Siemens Healthcare Diagnostics, Inc. (“Siemens”) today announced the full commercial launch of the Xprecia Stride™  Coagulation Analyzer following successful completion of its limited European release. The system will now be marketed through Siemens’ extensive sales and distribution network in a growing number of markets, currently excluding the U.S. (which will require FDA 510(k) clearance).

In addition, Siemens has today announced that the Xprecia Stride™  Coagulation Analyzer has been awarded the internationally respected Red Dot Award for Product Design for 2015. The Red Dot Product Design Competition started in Germany in 1954 and its award, the ‘Red Dot,’ is an internationally recognised quality seal. See www.red-dot.org for further details on the Red Dot competition and the award.

The Xprecia Stride™  Coagulation Analyzer delivers hand-held Prothrombin time testing (PT/INR) for point of-care monitoring and management of the oral anticoagulation therapy (OAT), Warfarin. The product was specifically designed to meet the growing demand for fast and reliable PT/INR results in physician offices and walk-in clinics to help healthcare professionals make informed decisions about patient care. Universal Biosensors will be the manufacturer of PT/INR strips for Siemens at the Company’s plant in Rowville, Victoria.

“The Xprecia Stride™ Coagulation Analyzer is among the most radical, user-friendly redesigns of a point of-care coagulation analyzer since they became widely available more than 20 years ago. This analyzer includes a number of innovations and features not found on most other point-of-care analyzers,” said David Stein, Ph.D., CEO of Siemens Diagnostics Point of Care Business Unit.

A copy of the press release by Siemens is attached.

UBI CEO Paul Wright said: “We are thrilled that the limited release has gone well and that Siemens will now be rolling out the Xprecia Stride™  Coagulation Analyzer. The Red Dot Award is a clear validation of the product’s unique features that will deliver real benefits to patients and healthcare professionals.”

The limited European release of the Xprecia Stride™  Coagulation Analyzer was initiated in December 2014.

Patients using Warfarin require frequent testing to assess the clotting tendency of their blood. The Prothrombin time (PT/INR) test allows physicians to adjust patient doses for diet and lifestyle changes. The worldwide point-of-care coagulation testing market was estimated at about US$1 billion in 2014 and is forecast to grow by about 9% per annum to about US$1.4 billion by 2018. The point-of-care coagulation testing market is dominated by PT/INR testing, which represents about 65% of this market.